Background: To investigate the clinical effects of norepinephrine versus dopamine in treatment of septic shock by pooling the data form open published clinical trials. Material and Methods: The clinical trials relevant to norepinephrine versus dopamine in treatment of septic shock were electronically searched in the databases of Pubmed, Embase, the Cochrane Library, Web of Science, Google scholar and CNKI. The original data related to the treatment effects such as death risk, oxygen metabolism and hemodynamics index were extracted from the included original studies. The death risk was pooled by the effect size of relative risk (RR), the oxygen metabolism and hemodynamics index were pooled by standard mean difference (SMD) and the corresponding 95% confidence interval (95%CI). The publication bias was evaluated by Begg’s funnel plot and Egger’s line regression test. Results: Thirteen clinical trials were included in the meta-analysis. The pooled results demonstrated the death risk was significantly decreased (RR=0.89, 95%CI:0.81 to 0.98, p=0.024) in septic shock patients who received norepinephrine compared to those receiving dopamine. The HR (SMD=-1.84, 95%CI:-2.86 to -0.81, p<0.01) and cardiac index (SMD=-0.74, 95%CI:-1.01 to -0.48, p<0.01) were lower in norepinephrine group compared to dopamine group. The systemic vascular resistance index (SMD=1.33, 95%CI:0.62 to 2.04, p<0.01) in norepinephrine group was higher than those of dopamine group with statistical difference. The Begg’s funnel plot and Egger’s line regression test (t=-0.84, p=0.425) showed no publication bias. Conclusions: Based on the present evidence, norepinephrine was superior to dopamine in the aspects of death risk reducing and hemodynamics.

中文翻译：

---

与多巴胺相比，去甲肾上腺素在败血症性休克治疗中的死亡风险降低和血液动力学方面更胜一筹

背景：通过汇总公开发表的临床试验数据来研究去甲肾上腺素与多巴胺对败血性休克的临床效果。材料和方法：在Pubmed，Embase，Cochrane图书馆，Web of Science，Google Scholar和CNKI的数据库中，以电子方式搜索了与去甲肾上腺素与多巴胺有关的败血性休克相关的临床试验。从包括的原始研究中提取与治疗效果相关的原始数据，例如死亡风险，氧代谢和血液动力学指数。死亡风险通过相对风险（RR）的影响大小进行汇总，氧代谢和血液动力学指数通过标准均值差（SMD）和相应的95％置信区间（95％CI）进行汇总。通过Begg的漏斗图和Egger的线回归检验评估出版偏倚。结果：荟萃分析包括13项临床试验。汇总结果表明，接受去甲肾上腺素治疗的败血性休克患者与接受多巴胺治疗的患者相比，死亡风险显着降低（RR = 0.89，95％CI：0.81至0.98，p = 0.024）。去甲肾上腺素组的HR（SMD = -1.84，95％CI：-2.86至-0.81，p <0.01）和心脏指数（SMD = -0.74，95％CI：-1.01至-0.48，p <0.01）较低与多巴胺组相比。去甲肾上腺素组的全身血管阻力指数（SMD = 1.33，95％CI：0.62至2.04，p <0.01）高于多巴胺组，差异有统计学意义。Begg的漏斗图和Egger的线回归检验（t = -0.84，p = 0.425）显示没有发布偏倚。结论：